Trials / Recruiting
RecruitingNCT07443085
Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery
Dose-Effect Relationship of Dexmedetomidine on Delirium and Cognitive Function After Lower Limb Orthopedic Surgeries for Elderly Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- Benha University · Academic / Other
- Sex
- All
- Age
- 55 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the dose-response relationship of Dexmedetomidine (DEX) in reducing the incidence and severity of postoperative delirium (POD) and postoperative cognitive dysfunction (POCD) in elderly patients. The study compares different doses of DEX against a fentanyl control group in patients undergoing major lower limb orthopedic surgery under general anesthesia to determine the optimal dosage for cognitive protection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexmedetomidine (Low dose) | Patients receive a specific low-dose intravenous infusion of Dexmedetomidine during major lower limb orthopedic surgery under opioid-based general anesthesia. The intervention aims to evaluate the dose-response relationship regarding its neuroprotective effects on postoperative delirium (POD). |
| DRUG | Dexmedetomidine (High dose) | Patients receive a higher-dose intravenous infusion of Dexmedetomidine during the surgical procedure. This arm is designed to determine if higher concentrations of DEX provide a more significant reduction in the incidence and severity of postoperative delirium and cognitive dysfunction compared to the lower dose. |
| DRUG | Fentanyl | Patients in this group receive standard opioid-based general anesthesia using fentanyl without the addition of Dexmedetomidine. This group serves as the baseline to compare the efficacy of DEX in preventing cognitive decline. |
Timeline
- Start date
- 2026-02-26
- Primary completion
- 2027-07-01
- Completion
- 2027-10-01
- First posted
- 2026-03-02
- Last updated
- 2026-03-02
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07443085. Inclusion in this directory is not an endorsement.